Brainstorm Cell Therapeutics (NASDAQ:BCLI) Announces Quarterly Earnings Results

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) released its quarterly earnings results on Monday. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04, reports.

Brainstorm Cell Therapeutics Trading Up 1.1%

Shares of Brainstorm Cell Therapeutics stock traded up $0.01 on Tuesday, hitting $0.96. 60,223 shares of the company traded hands, compared to its average volume of 19,801. The firm’s 50-day simple moving average is $0.91 and its 200 day simple moving average is $0.86. The company has a market cap of $14.22 million, a P/E ratio of -0.29 and a beta of 0.35. Brainstorm Cell Therapeutics has a 12-month low of $0.46 and a 12-month high of $1.69.

Brainstorm Cell Therapeutics Company Profile

(Get Free Report)

BrainStorm Cell Therapeutics is a biotechnology company focused on developing cell therapies for neurodegenerative diseases. Its lead program, NurOwn, is an investigational treatment designed to use a patient’s own bone marrow-derived mesenchymal stem cells, modified to produce neurotrophic factors that may support nerve cells. The company has primarily studied NurOwn for amyotrophic lateral sclerosis (ALS). The therapy has been evaluated in clinical trials, including a Phase 3 study; it is investigational and has not been established as an approved treatment.

Read More

Earnings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.